Galectin Therapeutics reported $9.93M in Operating Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Abbvie ABBV:US $ 11288M 2467M
Bristol Myers Squibb BMY:US $ 9.3B 202M
Galectin Therapeutics GALT:US $ 9.93M 2.51M
Gilead Sciences GILD:US $ 4231M 2162M
Idera Pharmaceuticals IDRA:US $ 5.36M 1.18M
Intercept Pharmaceuticals ICPT:US $ 85.12M 13.73M
Merk MRK:US $ 9666M 666M
Regulus Therapeutics RGLS:US $ 6.57M 391K
Vital Therapies VTL:US $ 20.61M 825K
YTE INCY:US $ 656.97M 40.27M